Catalysts

Catalysts - What Can Move the Stock

The next six months hinge on a single hard-dated event: Q1 FY2026 earnings on May 7, 2026 - eight days from today and the first clean print under the post-emergence equity. Management front-loaded 40-45% of the full FY2026 marketing budget into Q1 to push Clinical subscribers from ~130K toward ~200K, then reaffirmed FY26 guidance ($620-635M revenue, $105-115M EBITDA) on April 3, 2026 alongside the CEO departure. That print will resolve, in one report, whether this is a $98M cap option on a $110M EBITDA business or a melting subscriber base. The remainder of the calendar - a $40M term loan prepayment in execution, a Q2 goodwill/intangibles impairment test against a freshly written-up $529M base, and a still-vacant CEO seat - is supporting cast.

Catalyst Setup

Ranked Catalyst Timeline

The list is short on purpose. Below the top three, marginal value drops sharply: nothing on the calendar between Q1 results in May and the Q2 print/impairment test in August materially changes underwriting. The calendar quality is Medium-Thin: one decisive event near-term, then a 90-day quiet window, then a clustered Q2 reporting / impairment / governance update.

Impact Matrix

Binder Error: Could not ORDER BY column "CASE  WHEN ((linked_thesis = 'Both')) THEN (1) WHEN ((linked_thesis = 'Bear')) THEN (2) WHEN ((linked_thesis = 'Bull')) THEN (3) ELSE 4 END": add the expression/function to every SELECT, or move the UNION into a FROM clause.

Only two catalysts actually resolve the debate: the Q1 print and the Q2 impairment test. Everything else is information that scopes the debate without ending it. The capital allocation move is supporting evidence for the bull thesis; the CEO pick is a precondition for re-rate but not a re-rate by itself; the proxy meeting matters mainly for the comp signal.

Next 90 Days

Outside the May 7 print, the 90-day calendar is genuinely thin. The Q2 earnings report and the goodwill/intangibles impairment test - the next decision-grade events - sit roughly 105-120 days out. A PM that does not size the position for the May 7 print is choosing to sit out the cleanest catalyst in the file.

What Would Change the View

The two observable signals that would force the debate to update inside six months are Clinical subscriber count crossing 175K with Behavioral attrition decelerating below 12% YoY at the May 7 print (resolves the bull case as more than optionality and would re-rate toward 6x peer EV/EBITDA on $110M EBITDA), and any interim or annual impairment of Successor intangibles or goodwill against the freshly written-up $529M base in Q2 (validates the bear thesis that emergence-day forecasts were too generous and re-prices the equity off a smaller asset base). The third, lower-probability signal worth tracking is a permanent CEO appointment paired with a personal open-market equity purchase at or near today's price - a rerun of the Hawks $22.14 buy, except by an operator rather than a credit-fund principal. That combination would resolve the variant-perception debate about whether this is a workout situation under creditor control or a credible going concern, and is the single change in the file that would move governance from current grade D toward investable. Absent any of those three, the technical setup (50/200 death cross, 99% realized vol, $4.5M ADV) means the equity will continue to trade as a specialist event-driven instrument, not an institutional position.